Business · 16/10/1998
FDA Withdraws Conditional Approval of Erythrityl Tetranitrate Drug Applications
The FDA is withdrawing conditional approval of abbreviated new drug applications for single-entity erythrityl tetranitrate products due to insufficient evidence of their effectiveness in managing angina attacks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →